SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,655,576 | -29.5% | 458,373 | +1.7% | 2.07% | -19.8% |
| Q2 2023 | $9,436,772 | -0.1% | 450,873 | +0.8% | 2.58% | -8.9% |
| Q1 2023 | $9,442,182 | -17.0% | 447,073 | 0.0% | 2.83% | -11.7% |
| Q4 2022 | $11,378,008 | +33.2% | 447,073 | +25.8% | 3.20% | +39.5% |
| Q3 2022 | $8,542,000 | +19.7% | 355,487 | -4.2% | 2.30% | +18.1% |
| Q2 2022 | $7,138,000 | +10.4% | 370,987 | -0.3% | 1.94% | +15.4% |
| Q1 2022 | $6,465,000 | -0.4% | 371,987 | +25.4% | 1.68% | +3.2% |
| Q4 2021 | $6,491,000 | +320.9% | 296,535 | +267.4% | 1.63% | +299.0% |
| Q3 2021 | $1,542,000 | -39.2% | 80,702 | -45.4% | 0.41% | -22.8% |
| Q2 2021 | $2,536,000 | +97.2% | 147,702 | +156.9% | 0.53% | +73.8% |
| Q1 2021 | $1,286,000 | +479.3% | 57,500 | +475.0% | 0.30% | +362.1% |
| Q4 2020 | $222,000 | -85.4% | 10,000 | -90.3% | 0.07% | -86.6% |
| Q3 2020 | $1,516,000 | -71.6% | 102,713 | -71.5% | 0.49% | -68.0% |
| Q2 2020 | $5,335,000 | – | 360,000 | – | 1.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |